Metformina + Sitagliptina Ratiopharm

Metformin hydrochloride and sitagliptin, the active ingredient in Metformina + Sitagliptina Ratiopharm, is a biguanide and DPP‑4 inhibitor presented as an oral tablet formulation for oral use. It is indicated for the management of type 2 diabetes mellitus in adults. GNH USA supplies Metformina + Sitagliptina Ratiopharm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Metformina + Sitagliptina Ratiopharm is used in the treatment of type 2 diabetes mellitus, acting on glucose metabolism pathways. - Type 2 diabetes mellitus: improves overall glycaemic control and reduces HbA1c levels. - Adjunct to diet and exercise in type 2 diabetes: provides additional glucose lowering when metformin alone is insufficient. - Combination therapy for metabolic control: enhances insulin secretion and peripheral insulin sensitivity, aiding long‑term disease management.

Common Side Effects: - Gastrointestinal upset: nausea, abdominal discomfort, or diarrhea. - Headache: mild to moderate intensity. - Upper respiratory symptoms: nasopharyngitis or mild cough. - Dizziness: transient light‑headedness. - Fatigue: general tiredness.

Serious or Rare Side Effects: - Lactic acidosis: rare but potentially fatal metabolic disturbance. - Severe hypoglycaemia: especially when combined with insulin secretagogues. - Pancreatitis: acute inflammation of the pancreas. - Severe allergic reactions: rash, angioedema, or anaphylaxis. - Hepatic failure: marked liver enzyme elevation or dysfunction.

Before initiating therapy, consider patient‑specific factors and monitor appropriately. - Renal function: assess creatinine clearance; adjust or avoid in severe impairment. - Hepatic disease: use with caution; monitor liver enzymes. - Risk of lactic acidosis: avoid in conditions predisposing to hypoxia. - Elderly patients: start at lower dose and monitor for adverse events. - Alcohol consumption: limit intake to reduce lactic acidosis risk. - Store below 25°C: keep in the original pack, protect from moisture.

Metformina + Sitagliptina Ratiopharm may interact with several drug classes. Major Interactions (Avoid): - Iodinated contrast agents: may precipitate renal dysfunction when combined with metformin. - Insulin secretagogues (e.g., sulfonylureas): increase risk of severe hypoglycaemia. - Strong CYP2C8 inhibitors: may elevate sitagliptin plasma levels.

Moderate Interactions (Monitor Closely): - Diuretics: can affect renal clearance of metformin. - ACE inhibitors or ARBs: may enhance renal effects of metformin. - Warfarin: monitor INR as sitagliptin may alter anticoagulant effect.